The contact allergen nickel sensitizes primary human endothelial cells and keratinocytes to TRAIL-mediated apoptosis

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 6 B, 2010, Pages 1760-1776

  Schmidt, Marc ^a,b   Hupe, Mike ^c   Endres, Nicole ^a,b   Raghavan, Badrinarayanan ^a,b   Kavuri, Shyam ^c   Geserick, Peter ^c   Goebeler, Matthias ^a,b   Leverkus, Martin ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL GIESSEN   (Germany)

^c OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Apoptosis; C FLIP; Contact hypersensitivity; DISC; Endothelial cells; Nickel ions; TRAIL receptor

Indexed keywords

ALLERGEN; CASPASE 3; CASPASE 8; FLICE INHIBITORY PROTEIN; NICKEL; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL MEMBRANE; CYTOLOGY; DOWN REGULATION; DRUG EFFECT; ENDOTHELIUM CELL; ENZYMOLOGY; GENETIC TRANSCRIPTION; HUMAN; IMMUNOLOGY; KERATINOCYTE; METABOLISM; PROTEIN PROCESSING; UMBILICAL VEIN;

ALLERGENS; APOPTOSIS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CASPASE 3; CASPASE 8; CELL MEMBRANE; CELLS, CULTURED; DOWN-REGULATION; ENDOTHELIAL CELLS; HUMANS; KERATINOCYTES; NICKEL; PROTEIN PROCESSING, POST-TRANSLATIONAL; RNA, SMALL INTERFERING; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TRANSCRIPTION, GENETIC; UMBILICAL VEINS;

EID: 77955160216     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2009.00823.x     Document Type: Article

References (50)

1. Krob HA, Fleischer AB, D'Agostino R. Prevalence and relevance of contact dermatitis allergens: a meta-analysis of 15 years of published T.R.U.E. test data. J Am Acad Dermatol. 2004, 51:349-53.
2. Larese F, Gianpietro A, Venier M. In vitro percutaneous absorption of metal compounds. Toxicol Lett. 2007, 170:49-56.
3. Koster R, Vieluf D, Kiehn M. Nickel and molybdenum contact allergies in patients with coronary in-stent restenosis. Lancet. 2000, 356:1895-7.
4. Hostynek JJ. Sensitization to nickel: etiology, epidemiology, immune reactions, prevention, and therapy. Rev Environ Health. 2006, 21:253-80.
5. Goebeler M, Roth J, Brocker EB. Activation of nuclear factor-kappa B and gene expression in human endothelial cells by the common haptens nickel and cobalt. J Immunol. 1995, 155:2459-67.
6. Viemann D, Schmidt M, Tenbrock K. The contact allergen nickel triggers a unique inflammatory and proangiogenic gene expression pattern via activation of NF-kappaB and hypoxia-inducible factor-1alpha. J Immunol. 2007, 178:3198-207.
7. Goebeler M, Gillitzer R, Kilian K. Multiple signaling pathways regulate NF-kappaB-dependent transcription of the monocyte chemoattractant protein-1 gene in primary endothelial cells. Blood. 2001, 97:46-55.
8. Kimberley FC, Screaton GR. Following a TRAIL: update on a ligand and its five receptors. Cell Res. 2004, 14:359-72.
9. Wajant H. TRAIL and NFkappaB signaling-a complex relationship. Vitam Horm. 2004, 67:101-32.
10. Merino D, Lalaoui N, Morizot A. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol. 2006, 26:7046-55.
11. Budd RC, Yeh WC, Tschopp J. cFLIP regulation of lymphocyte activation and development. Nat Rev Immunol. 2006, 6:196-204.
12. Johnstone RW, Frew AJ, Smyth MJ. The TRAIL apoptotic pathway in cancer onset, progression and therapy. Nat Rev Cancer. 2008, 8:782-98.
13. Leverkus M, Diessenbacher P, Geserick P. FLIP ing the coin? Death receptor-mediated signals during skin tumorigenesis. Exp Dermatol. 2008, 17:614-22.
14. Leverkus M, Sprick MR, Wachter T. Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation. Mol Cell Biol. 2003, 23:777-90.
15. Walczak H, Miller RE, Ariail K. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med. 1999, 5:157-63.
16. Wachter T, Sprick M, Hausmann D. cFLIPL inhibits tumor necrosis factor-related apoptosis-inducing ligand-mediated NF-kappaB activation at the death-inducing signaling complex in human keratinocytes. J Biol Chem. 2004, 279:52824-34.
17. Leverkus M, McLellan AD, Heldmann M. MHC class II-mediated apoptosis in dendritic cells: a role for membrane-associated and mitochondrial signaling pathways. Int Immunol. 2003, 15:993-1006.
18. Gerin PA, Gilligan MG, Searle PF. Improved titers of retroviral vectors from the human FLYRD18 packaging cell line in serum- and protein-free medium. Hum Gene Ther. 1999, 10:1965-74.
19. Liu W, Saint DA. A new quantitative method of real time reverse transcription polymerase chain reaction assay based on simulation of polymerase chain reaction kinetics. Anal Biochem. 2002, 302:52-9.
20. Ganten TM, Haas TL, Sykora J. Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs. Cell Death Differ. 2004, 11:S86-S96.
21. Washburn B, Weigand MA, Grosse-Wilde A. TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus. J Immunol. 2003, 170:1814-21.
22. Dinter A, Berger EG. Golgi-disturbing agents. Histochem Cell Biol. 1998, 109:571-90.
23. Leverkus M, Neumann M, Mengling T. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res. 2000, 60:553-9.
24. Yeh WC, Itie A, Elia AJ. Requirement for Casper (c-FLIP) in regulation of death receptor-induced apoptosis and embryonic development. Immunity. 2000, 12:633-42.
25. Kreuz S, Siegmund D, Scheurich P. NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol Cell Biol. 2001, 21:3964-73.
26. Leverkus M, Sprick MR, Wachter T. TRAIL-induced apoptosis and gene induction in HaCaT keratinocytes: differential contribution of TRAIL receptors 1 and 2. J Invest Dermatol. 2003, 121:149-55.
27. Kataoka T. The caspase-8 modulator c-FLIP. Crit Rev Immunol. 2005, 25:31-58.
28. Debatin KM, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene. 2004, 23:2950-66.
29. Chang DW, Xing Z, Pan Y. c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J. 2002, 21:3704-14.
30. Micheau O, Thome M, Schneider P. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem. 2002, 277:45162-71.
31. Krueger A, Baumann S, Krammer PH. FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis. Mol Cell Biol. 2001, 21:8247-54.
32. Krueger A, Schmitz I, Baumann S. Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem. 2001, 276:20633-40.
33. Geserick P, Drewniok C, Hupe M. Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- or CD95L-mediated apoptosis. Oncogene. 2008, 27:3211-20.
34. Trautmann A, Akdis M, Kleemann D. T cell-mediated Fas-induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. J Clin Invest. 2000, 106:25-35.
35. Secchiero P, Gonelli A, Carnevale E. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation. 2003, 107:2250-6.
36. Alladina SJ, Song JH, Davidge ST. TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2. J Vasc Res. 2005, 42:337-47.
37. Zhang XD, Nguyen T, Thomas WD. Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett. 2000, 482:193-9.
38. Clancy L, Mruk K, Archer K. Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc Natl Acad Sci USA. 2005, 102:18099-104.
39. Koschny R, Sykora J, Walczak H. Bortezomib-mediated up-regulation of TRAIL-R1 and TRAIL-R2 is not necessary for but contributes to sensitization of primary human glioma cells to TRAIL. Clin Cancer Res. 2007, 13:6541-2.
40. Inoue S, Twiddy D, Dyer MJ. Upregulation of TRAIL-R2 is not involved in HDACi mediated sensitization to TRAIL-induced apoptosis. Cell Death Differ. 2006, 13:2160-2.
41. Inoue S, Macfarlane M, Harper N. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ. 2004, 11:S193-S206.
42. Guan B, Yue P, Lotan R. Evidence that the human death receptor 4 is regulated by activator protein 1. Oncogene. 2002, 21:3121-9.
43. Skurk C, Maatz H, Kim HS. The Akt-regulated forkhead transcription factor FOXO3a controls endothelial cell viability through modulation of the caspase-8 inhibitor FLIP. J Biol Chem. 2004, 279:1513-25.
44. Borrelli S, Candi E, Alotto D. p63 regulates the caspase-8-FLIP apoptotic pathway in epidermis. Cell Death Differ. 2009, 16:253-63.
45. Aoudjit F, Vuori K. Matrix attachment regulates Fas-induced apoptosis in endothelial cells: a role for c-flip and implications for anoikis. J Cell Biol. 2001, 152:633-43.
46. Suhara T, Mano T, Oliveira BE. Phosphatidylinositol 3-kinase/Akt signaling controls endothelial cell sensitivity to Fas-mediated apoptosis via regulation of FLICE-inhibitory protein (FLIP). Circ Res. 2001, 89:13-9.
47. Armbruster N, Trautmann A, Brocker EB. Suprabasal spongiosis in acute eczematous dermatitis: cFLIP maintains resistance of basal keratinocytes to t-cell-mediated apoptosis. J Invest Dermatol. 2009, 10.1038/jid.2008.438, doi
48. Kerstan A, Leverkus M, Trautmann A. Effector pathways during eczematous dermatitis: where inflammation meets cell death. Exp Dermatol. 2009, 18:893-9.
49. Farley SM, Dotson AD, Purdy DE. Fas ligand elicits a caspase-independent proinflammatory response in human keratinocytes: implications for dermatitis. J Invest Dermatol. 2006, 126:2438-51.
50. Gochuico BR, Zhang J, Ma BY. TRAIL expression in vascular smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2000, 278:L1045-50.